Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Beam Therapeutics (BEAM) over the last 6 years, with Q3 2025 value amounting to $14.1 million.

  • Beam Therapeutics' Non Operating Income rose 4317.81% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.6 million, marking a year-over-year increase of 2755.21%. This contributed to the annual value of $38.9 million for FY2024, which is 1425.07% down from last year.
  • As of Q3 2025, Beam Therapeutics' Non Operating Income stood at $14.1 million, which was up 4317.81% from $17.9 million recorded in Q2 2025.
  • Beam Therapeutics' Non Operating Income's 5-year high stood at $51.6 million during Q4 2022, with a 5-year trough of -$17.3 million in Q2 2021.
  • Over the past 5 years, Beam Therapeutics' median Non Operating Income value was $10.0 million (recorded in 2022), while the average stood at $11.9 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 11781.17% in 2021, then soared by 432207.69% in 2022.
  • Quarter analysis of 5 years shows Beam Therapeutics' Non Operating Income stood at -$1.2 million in 2021, then soared by 4322.08% to $51.6 million in 2022, then tumbled by 78.11% to $11.3 million in 2023, then decreased by 14.35% to $9.7 million in 2024, then surged by 45.44% to $14.1 million in 2025.
  • Its Non Operating Income was $14.1 million in Q3 2025, compared to $17.9 million in Q2 2025 and $10.0 million in Q1 2025.